home / stock / itrm / itrm news

ITRM News and Press, Iterum Therapeutics plc From 07/02/25

Stock Information
Company Name: Iterum Therapeutics plc
Stock Symbol: ITRM
Market: NASDAQ
Website: iterumtx.com
Menu
ITRM ITRM Quote ITRM Short ITRM News ITRM Articles ITRM Message Board
Get ITRM Alerts

News, Short Squeeze, Breakout and More Instantly...
ITRM - Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today ann...
ITRM - Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH(TM) Launch and Commercial Growth

DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today ann...

ITRM - Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

DUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both commun...

ITRM - Iterum Therapeutics Announces Partnership for Commercialization Services

U.S. Commercial Launch of ORLYNVAH TM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” o...
ITRM - Iterum Therapeutics Announces Extension of Term of Promissory Note

DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both communi...

ITRM - Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026

2025-05-13 13:44:38 ET More on Iterum Therapeutics Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript Iterum Therapeutics Non-GAAP EPS of -$0.10 Seeking Alpha’s Quant Rating on Iterum Therapeutics Historical earnings data for Iterum Therap...

ITRM - Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript

2025-05-13 13:44:05 ET Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Conference Call May 13, 2025, 08:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Confere...
ITRM - Iterum Therapeutics Non-GAAP EPS of -$0.10

2025-05-13 07:05:31 ET More on Iterum Therapeutics Seeking Alpha’s Quant Rating on Iterum Therapeutics Historical earnings data for Iterum Therapeutics Financial information for Iterum Therapeutics Read the full article on Seeking Alpha For fur...

ITRM - Expected US Company Earnings on Tuesday, May 13th, 2025

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

ITRM - Iterum Therapeutics Reports First Quarter 2025 Financial Results

--Preparing for Potential Launch of ORLYNVAH TM by Q4 2025-- - -Extended Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a comp...
Previous 10 Next 10